APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dopamine Agonists

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Dopamine Agonists Industry Growth and Trends Forecast to 2032

2 January 2026100 pages

Choose your research edition.

Industry ResearchDopamine Agonists Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Dopamine Agonists Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Dopamine Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dopamine Agonists Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Dopamine Agonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Dopamine Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Dopamine Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Dopamine Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dopamine Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dopamine Agonists include ACADIA Pharmaceuticals Inc, Impax Laboratories, Kissei Pharmaceutical Co, UCB, AbbVie, Boehringer Ingelheim, Otsuka Pharmaceutical Co, GSK and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Dopamine Agonists market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Dopamine Agonists market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Dopamine Agonists market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Dopamine Agonists.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Dopamine Agonists market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Dopamine Agonists Market by Company

ACADIA Pharmaceuticals Inc

Impax Laboratories

Kissei Pharmaceutical Co

UCB

AbbVie

Boehringer Ingelheim

Otsuka Pharmaceutical Co

GSK

Pfizer

Roche

Merck

Teva Pharmaceutical Industries Ltd

Dopamine Agonists Segment by Type

Ergotamine

Non-ergotamine

Dopamine Agonists Segment by Application

Parkinson's

Restless Legs Syndrome

Dopamine Agonists Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dopamine Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dopamine Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dopamine Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dopamine Agonists manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Dopamine Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ergotamine Table 2. Major Company of Non-ergotamine Table 3. Global Dopamine Agonists Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Dopamine Agonists Sales by Type (2021-2026) & (W Units) Table 5. Global Dopamine Agonists Sales Market Share in Volume by Type (2021-2026) Table 6. Global Dopamine Agonists Sales by Type (2021-2026) & (US$ Million) Table 7. Global Dopamine Agonists Sales Market Share in Value by Type (2021-2026) Table 8. Global Dopamine Agonists Price by Type (2021-2026) & (US$/Unit) Table 9. Global Dopamine Agonists Sales by Type (2027-2032) & (W Units) Table 10. Global Dopamine Agonists Sales Market Share in Volume by Type (2027-2032) Table 11. Global Dopamine Agonists Sales by Type (2027-2032) & (US$ Million) Table 12. Global Dopamine Agonists Sales Market Share in Value by Type (2027-2032) Table 13. Global Dopamine Agonists Price by Type (2027-2032) & (US$/Unit) Table 14. North America Dopamine Agonists Sales by Type (2021-2026) & (W Units) Table 15. North America Dopamine Agonists Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Dopamine Agonists Sales by Type (2021-2026) & (W Units) Table 17. Europe Dopamine Agonists Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Dopamine Agonists Sales by Type (2021-2026) & (W Units) Table 19. Asia-Pacific Dopamine Agonists Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Dopamine Agonists Sales by Type (2021-2026) & (W Units) Table 21. Latin America Dopamine Agonists Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Dopamine Agonists Sales by Type (2021-2026) & (W Units) Table 23. Middle East and Africa Dopamine Agonists Sales by Type (2021-2026) & (US$ Million) Table 24. Dopamine Agonists Industry Trends Table 25. Dopamine Agonists Industry Drivers Table 26. Dopamine Agonists Industry Opportunities and Challenges Table 27. Dopamine Agonists Industry Restraints Table 28. Global Dopamine Agonists Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Dopamine Agonists Revenue Market Share by Company (2021-2026) Table 30. Global Dopamine Agonists Sales by Company (2021-2026) & (W Units) Table 31. Global Dopamine Agonists Sales Share by Company (2021-2026) Table 32. Global Dopamine Agonists Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Dopamine Agonists Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Dopamine Agonists Major Company Production Sites and Headquarters Table 35. Global Dopamine Agonists Company, Product Type & Application Table 36. Global Dopamine Agonists Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Dopamine Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Dopamine Agonists Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Dopamine Agonists Sales by Region (2021-2026) & (W Units) Table 41. Global Dopamine Agonists Sales Market Share in Volume by Region (2021-2026) Table 42. Global Dopamine Agonists Sales by Region (2021-2026) & (US$ Million) Table 43. Global Dopamine Agonists Sales Market Share in Value by Region (2021-2026) Table 44. Global Dopamine Agonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Dopamine Agonists Sales by Region (2027-2032) & (W Units) Table 46. Global Dopamine Agonists Sales Market Share in Volume by Region (2027-2032) Table 47. Global Dopamine Agonists Sales by Region (2027-2032) & (US$ Million) Table 48. Global Dopamine Agonists Sales Market Share in Value by Region (2027-2032) Table 49. Global Dopamine Agonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Dopamine Agonists Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Dopamine Agonists Sales by Application (2021-2026) & (W Units) Table 52. Global Dopamine Agonists Sales Market Share in Volume by Application (2021-2026) Table 53. Global Dopamine Agonists Sales by Application (2021-2026) & (US$ Million) Table 54. Global Dopamine Agonists Sales Market Share in Value by Application (2021-2026) Table 55. Global Dopamine Agonists Price by Application (2021-2026) & (US$/Unit) Table 56. Global Dopamine Agonists Sales by Application (2027-2032) & (W Units) Table 57. Global Dopamine Agonists Sales Market Share in Volume by Application (2027-2032) Table 58. Global Dopamine Agonists Sales by Application (2027-2032) & (US$ Million) Table 59. Global Dopamine Agonists Sales Market Share in Value by Application (2027-2032) Table 60. Global Dopamine Agonists Price by Application (2027-2032) & (US$/Unit) Table 61. North America Dopamine Agonists Sales by Application (2021-2026) & (W Units) Table 62. North America Dopamine Agonists Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Dopamine Agonists Sales by Application (2021-2026) & (W Units) Table 64. Europe Dopamine Agonists Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Dopamine Agonists Sales by Application (2021-2026) & (W Units) Table 66. Asia-Pacific Dopamine Agonists Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Dopamine Agonists Sales by Application (2021-2026) & (W Units) Table 68. Latin America Dopamine Agonists Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Dopamine Agonists Sales by Application (2021-2026) & (W Units) Table 70. Middle East and Africa Dopamine Agonists Sales by Application (2021-2026) & (US$ Million) Table 71. ACADIA Pharmaceuticals Inc Company Information Table 72. ACADIA Pharmaceuticals Inc Business Overview Table 73. ACADIA Pharmaceuticals Inc Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. ACADIA Pharmaceuticals Inc Dopamine Agonists Product Portfolio Table 75. ACADIA Pharmaceuticals Inc Recent Development Table 76. Impax Laboratories Company Information Table 77. Impax Laboratories Business Overview Table 78. Impax Laboratories Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Impax Laboratories Dopamine Agonists Product Portfolio Table 80. Impax Laboratories Recent Development Table 81. Kissei Pharmaceutical Co Company Information Table 82. Kissei Pharmaceutical Co Business Overview Table 83. Kissei Pharmaceutical Co Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Kissei Pharmaceutical Co Dopamine Agonists Product Portfolio Table 85. Kissei Pharmaceutical Co Recent Development Table 86. UCB Company Information Table 87. UCB Business Overview Table 88. UCB Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. UCB Dopamine Agonists Product Portfolio Table 90. UCB Recent Development Table 91. AbbVie Company Information Table 92. AbbVie Business Overview Table 93. AbbVie Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AbbVie Dopamine Agonists Product Portfolio Table 95. AbbVie Recent Development Table 96. Boehringer Ingelheim Company Information Table 97. Boehringer Ingelheim Business Overview Table 98. Boehringer Ingelheim Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Boehringer Ingelheim Dopamine Agonists Product Portfolio Table 100. Boehringer Ingelheim Recent Development Table 101. Otsuka Pharmaceutical Co Company Information Table 102. Otsuka Pharmaceutical Co Business Overview Table 103. Otsuka Pharmaceutical Co Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Otsuka Pharmaceutical Co Dopamine Agonists Product Portfolio Table 105. Otsuka Pharmaceutical Co Recent Development Table 106. GSK Company Information Table 107. GSK Business Overview Table 108. GSK Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. GSK Dopamine Agonists Product Portfolio Table 110. GSK Recent Development Table 111. Pfizer Company Information Table 112. Pfizer Business Overview Table 113. Pfizer Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Pfizer Dopamine Agonists Product Portfolio Table 115. Pfizer Recent Development Table 116. Roche Company Information Table 117. Roche Business Overview Table 118. Roche Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Roche Dopamine Agonists Product Portfolio Table 120. Roche Recent Development Table 121. Merck Company Information Table 122. Merck Business Overview Table 123. Merck Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Merck Dopamine Agonists Product Portfolio Table 125. Merck Recent Development Table 126. Teva Pharmaceutical Industries Ltd Company Information Table 127. Teva Pharmaceutical Industries Ltd Business Overview Table 128. Teva Pharmaceutical Industries Ltd Dopamine Agonists Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Teva Pharmaceutical Industries Ltd Dopamine Agonists Product Portfolio Table 130. Teva Pharmaceutical Industries Ltd Recent Development Table 131. North America Dopamine Agonists Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 132. North America Dopamine Agonists Sales by Country (2021-2026) & (W Units) Table 133. North America Dopamine Agonists Sales Market Share by Country (2021-2026) Table 134. North America Dopamine Agonists Sales Forecast by Country (2027-2032) & (W Units) Table 135. North America Dopamine Agonists Sales Market Share Forecast by Country (2027-2032) Table 136. North America Dopamine Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America Dopamine Agonists Market Size by Country (2021-2026) & (US$ Million) Table 138. North America Dopamine Agonists Market Share by Country (2021-2026) Table 139. North America Dopamine Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America Dopamine Agonists Market Share Forecast by Country (2027-2032) Table 141. Europe Dopamine Agonists Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 142. Europe Dopamine Agonists Sales by Country (2021-2026) & (W Units) Table 143. Europe Dopamine Agonists Sales Market Share by Country (2021-2026) Table 144. Europe Dopamine Agonists Sales Forecast by Country (2027-2032) & (W Units) Table 145. Europe Dopamine Agonists Sales Market Share Forecast by Country (2027-2032) Table 146. Europe Dopamine Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe Dopamine Agonists Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe Dopamine Agonists Market Share by Country (2021-2026) Table 149. Europe Dopamine Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe Dopamine Agonists Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Dopamine Agonists Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Dopamine Agonists Sales by Country (2021-2026) & (W Units) Table 153. Asia-Pacific Dopamine Agonists Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific Dopamine Agonists Sales Forecast by Country (2027-2032) & (W Units) Table 155. Asia-Pacific Dopamine Agonists Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Dopamine Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Dopamine Agonists Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific Dopamine Agonists Market Share by Country (2021-2026) Table 159. Asia-Pacific Dopamine Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific Dopamine Agonists Market Share Forecast by Country (2027-2032) Table 161. Latin America Dopamine Agonists Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 162. Latin America Dopamine Agonists Sales by Country (2021-2026) & (W Units) Table 163. Latin America Dopamine Agonists Sales Market Share by Country (2021-2026) Table 164. Latin America Dopamine Agonists Sales Forecast by Country (2027-2032) & (W Units) Table 165. Latin America Dopamine Agonists Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America Dopamine Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America Dopamine Agonists Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America Dopamine Agonists Market Share by Country (2021-2026) Table 169. Latin America Dopamine Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America Dopamine Agonists Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Dopamine Agonists Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Dopamine Agonists Sales by Country (2021-2026) & (W Units) Table 173. Middle East and Africa Dopamine Agonists Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa Dopamine Agonists Sales Forecast by Country (2027-2032) & (W Units) Table 175. Middle East and Africa Dopamine Agonists Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Dopamine Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Dopamine Agonists Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa Dopamine Agonists Market Share by Country (2021-2026) Table 179. Middle East and Africa Dopamine Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa Dopamine Agonists Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. Dopamine Agonists Distributors List Table 184. Dopamine Agonists Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Dopamine Agonists Image Figure 2. Global Dopamine Agonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dopamine Agonists Market Size (2021-2032) & (US$ Million) Figure 4. Global Dopamine Agonists Sales (2021-2032) & (W Units) Figure 5. Ergotamine Image Figure 6. Global Ergotamine Sales YoY Growth (2021-2032) & (W Units) Figure 7. Non-ergotamine Image Figure 8. Global Non-ergotamine Sales YoY Growth (2021-2032) & (W Units) Figure 9. Global Dopamine Agonists Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Dopamine Agonists Market Share by Type 2025 VS 2032 Figure 11. North America Dopamine Agonists Sales Market Share in Volume by Type in 2025 Figure 12. North America Dopamine Agonists Sales Market Share in Value by Type in 2025 Figure 13. Europe Dopamine Agonists Sales Market Share in Volume by Type in 2025 Figure 14. Europe Dopamine Agonists Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Dopamine Agonists Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Dopamine Agonists Sales Market Share in Value by Type in 2025 Figure 17. Latin America Dopamine Agonists Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Dopamine Agonists Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Dopamine Agonists Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Dopamine Agonists Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Dopamine Agonists Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Parkinson's Image Figure 24. Global Parkinson's Sales YoY Growth (2021-2032) & (W Units) Figure 25. Restless Legs Syndrome Image Figure 26. Global Restless Legs Syndrome Sales YoY Growth (2021-2032) & (W Units) Figure 27. Global Dopamine Agonists Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Dopamine Agonists Market Share by Application 2025 VS 2032 Figure 29. North America Dopamine Agonists Sales Market Share in Volume by Application in 2025 Figure 30. North America Dopamine Agonists Sales Market Share in Value by Application in 2025 Figure 31. Europe Dopamine Agonists Sales Market Share in Volume by Application in 2025 Figure 32. Europe Dopamine Agonists Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Dopamine Agonists Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Dopamine Agonists Sales Market Share in Value by Application in 2025 Figure 35. Latin America Dopamine Agonists Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Dopamine Agonists Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Dopamine Agonists Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Dopamine Agonists Sales Market Share in Value by Application in 2025 Figure 39. North America Dopamine Agonists Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 40. North America Dopamine Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Dopamine Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Dopamine Agonists Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 44. Europe Dopamine Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Dopamine Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Dopamine Agonists Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 48. Asia-Pacific Dopamine Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Dopamine Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Dopamine Agonists Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. Latin America Dopamine Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Dopamine Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Dopamine Agonists Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Middle East and Africa Dopamine Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Dopamine Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Dopamine Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Dopamine Agonists Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Dopamine Agonists Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Ergotamine
  • Non-ergotamine
Applications
  • Parkinson's
  • Restless Legs Syndrome
Companies covered
  • ACADIA Pharmaceuticals Inc
  • Impax Laboratories
  • Kissei Pharmaceutical Co
  • UCB
  • AbbVie
  • Boehringer Ingelheim
  • Otsuka Pharmaceutical Co
  • GSK
  • Pfizer
  • Roche
  • Merck
  • Teva Pharmaceutical Industries Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dopamine Agonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Dopamine Agonists Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Dopamine Agonists Market by Type
  6. 1.3.1 Ergotamine
  7. 1.3.2 Non-ergotamine
  8. 1.4 Global Dopamine Agonists Market Size by Type
  9. 1.4.1 Global Dopamine Agonists Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Dopamine Agonists Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Dopamine Agonists Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Dopamine Agonists Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Dopamine Agonists Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Dopamine Agonists Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Dopamine Agonists Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Dopamine Agonists Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Dopamine Agonists Industry Trends
  2. 2.2 Dopamine Agonists Industry Drivers
  3. 2.3 Dopamine Agonists Industry Opportunities and Challenges
  4. 2.4 Dopamine Agonists Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Dopamine Agonists Revenue (2021-2026)
  2. 3.2 Global Top Players by Dopamine Agonists Sales (2021-2026)
  3. 3.3 Global Top Players by Dopamine Agonists Price (2021-2026)
  4. 3.4 Global Dopamine Agonists Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dopamine Agonists Major Company Production Sites & Headquarters
  6. 3.6 Global Dopamine Agonists Company, Product Type & Application
  7. 3.7 Global Dopamine Agonists Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dopamine Agonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dopamine Agonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dopamine Agonists Tier 1, Tier 2, and Tier 3
4 Dopamine Agonists Regional Status and Outlook
  1. 4.1 Global Dopamine Agonists Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Dopamine Agonists Historic Market Size by Region
  3. 4.2.1 Global Dopamine Agonists Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Dopamine Agonists Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Dopamine Agonists Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Dopamine Agonists Forecasted Market Size by Region
  7. 4.3.1 Global Dopamine Agonists Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Dopamine Agonists Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Dopamine Agonists Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Dopamine Agonists by Application
  1. 5.1 Dopamine Agonists Market by Application
  2. 5.1.1 Parkinson's
  3. 5.1.2 Restless Legs Syndrome
  4. 5.2 Global Dopamine Agonists Market Size by Application
  5. 5.2.1 Global Dopamine Agonists Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Dopamine Agonists Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Dopamine Agonists Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Dopamine Agonists Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Dopamine Agonists Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Dopamine Agonists Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Dopamine Agonists Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Dopamine Agonists Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ACADIA Pharmaceuticals Inc
  2. 6.1.1 ACADIA Pharmaceuticals Inc Company Information
  3. 6.1.2 ACADIA Pharmaceuticals Inc Business Overview
  4. 6.1.3 ACADIA Pharmaceuticals Inc Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ACADIA Pharmaceuticals Inc Dopamine Agonists Product Portfolio
  6. 6.1.5 ACADIA Pharmaceuticals Inc Recent Developments
  7. 6.2 Impax Laboratories
  8. 6.2.1 Impax Laboratories Company Information
  9. 6.2.2 Impax Laboratories Business Overview
  10. 6.2.3 Impax Laboratories Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Impax Laboratories Dopamine Agonists Product Portfolio
  12. 6.2.5 Impax Laboratories Recent Developments
  13. 6.3 Kissei Pharmaceutical Co
  14. 6.3.1 Kissei Pharmaceutical Co Company Information
  15. 6.3.2 Kissei Pharmaceutical Co Business Overview
  16. 6.3.3 Kissei Pharmaceutical Co Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Kissei Pharmaceutical Co Dopamine Agonists Product Portfolio
  18. 6.3.5 Kissei Pharmaceutical Co Recent Developments
  19. 6.4 UCB
  20. 6.4.1 UCB Company Information
  21. 6.4.2 UCB Business Overview
  22. 6.4.3 UCB Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 UCB Dopamine Agonists Product Portfolio
  24. 6.4.5 UCB Recent Developments
  25. 6.5 AbbVie
  26. 6.5.1 AbbVie Company Information
  27. 6.5.2 AbbVie Business Overview
  28. 6.5.3 AbbVie Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AbbVie Dopamine Agonists Product Portfolio
  30. 6.5.5 AbbVie Recent Developments
  31. 6.6 Boehringer Ingelheim
  32. 6.6.1 Boehringer Ingelheim Company Information
  33. 6.6.2 Boehringer Ingelheim Business Overview
  34. 6.6.3 Boehringer Ingelheim Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Boehringer Ingelheim Dopamine Agonists Product Portfolio
  36. 6.6.5 Boehringer Ingelheim Recent Developments
  37. 6.7 Otsuka Pharmaceutical Co
  38. 6.7.1 Otsuka Pharmaceutical Co Company Information
  39. 6.7.2 Otsuka Pharmaceutical Co Business Overview
  40. 6.7.3 Otsuka Pharmaceutical Co Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Otsuka Pharmaceutical Co Dopamine Agonists Product Portfolio
  42. 6.7.5 Otsuka Pharmaceutical Co Recent Developments
  43. 6.8 GSK
  44. 6.8.1 GSK Company Information
  45. 6.8.2 GSK Business Overview
  46. 6.8.3 GSK Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GSK Dopamine Agonists Product Portfolio
  48. 6.8.5 GSK Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Dopamine Agonists Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Roche
  56. 6.10.1 Roche Company Information
  57. 6.10.2 Roche Business Overview
  58. 6.10.3 Roche Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Roche Dopamine Agonists Product Portfolio
  60. 6.10.5 Roche Recent Developments
  61. 6.11 Merck
  62. 6.11.1 Merck Company Information
  63. 6.11.2 Merck Business Overview
  64. 6.11.3 Merck Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Merck Dopamine Agonists Product Portfolio
  66. 6.11.5 Merck Recent Developments
  67. 6.12 Teva Pharmaceutical Industries Ltd
  68. 6.12.1 Teva Pharmaceutical Industries Ltd Company Information
  69. 6.12.2 Teva Pharmaceutical Industries Ltd Business Overview
  70. 6.12.3 Teva Pharmaceutical Industries Ltd Dopamine Agonists Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Teva Pharmaceutical Industries Ltd Dopamine Agonists Product Portfolio
  72. 6.12.5 Teva Pharmaceutical Industries Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Dopamine Agonists Sales by Country
  2. 7.1.1 North America Dopamine Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Dopamine Agonists Sales by Country (2021-2026)
  4. 7.1.3 North America Dopamine Agonists Sales Forecast by Country (2027-2032)
  5. 7.2 North America Dopamine Agonists Market Size by Country
  6. 7.2.1 North America Dopamine Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Dopamine Agonists Market Size by Country (2021-2026)
  8. 7.2.3 North America Dopamine Agonists Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Dopamine Agonists Sales by Country
  2. 8.1.1 Europe Dopamine Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Dopamine Agonists Sales by Country (2021-2026)
  4. 8.1.3 Europe Dopamine Agonists Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Dopamine Agonists Market Size by Country
  6. 8.2.1 Europe Dopamine Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Dopamine Agonists Market Size by Country (2021-2026)
  8. 8.2.3 Europe Dopamine Agonists Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Dopamine Agonists Sales by Country
  2. 9.1.1 Asia-Pacific Dopamine Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Dopamine Agonists Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Dopamine Agonists Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Dopamine Agonists Market Size by Country
  6. 9.2.1 Asia-Pacific Dopamine Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Dopamine Agonists Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Dopamine Agonists Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Dopamine Agonists Sales by Country
  2. 10.1.1 South America Dopamine Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Dopamine Agonists Sales by Country (2021-2026)
  4. 10.1.3 South America Dopamine Agonists Sales Forecast by Country (2027-2032)
  5. 10.2 South America Dopamine Agonists Market Size by Country
  6. 10.2.1 South America Dopamine Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Dopamine Agonists Market Size by Country (2021-2026)
  8. 10.2.3 South America Dopamine Agonists Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Dopamine Agonists Sales by Country
  2. 11.1.1 Middle East and Africa Dopamine Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Dopamine Agonists Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Dopamine Agonists Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Dopamine Agonists Market Size by Country
  6. 11.2.1 Middle East and Africa Dopamine Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Dopamine Agonists Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Dopamine Agonists Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Dopamine Agonists Value Chain Analysis
  2. 12.1.1 Dopamine Agonists Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Dopamine Agonists Production Mode & Process
  7. 12.2 Dopamine Agonists Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Dopamine Agonists Distributors
  10. 12.2.3 Dopamine Agonists Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst